Regulatory information – adjusted fees for applications to EMA from 1 April 2024

The European Medicines Agency (EMA) reminds applicants and marketing authorisation holders that adjusted fees for all applications, except for pharmacovigilance procedures, will be coming into effect on 1 April 2024.
News Corporate

The European Medicines Agency (EMA) reminds applicants and marketing authorisation holders that adjusted fees for all applications, except for pharmacovigilance procedures, will be coming into effect on 1 April 2024.

Every year, the European Commission adopts a regulation adjusting the fees payable to the Agency with reference to the inflation rate in the European Union for the previous year. The 2023 inflation rate was 3.4%.

EMA published full details of the revised fees following the adoption of the Commission Regulation (EU) 2024/848 of 14 March 2024 amending Council Regulation (EC) No 297/95 as regards the adjustment of the fees of the European Medicines Agency to the inflation rate with effect from 1 April 2024. The Agency's Management Board decided on the implementation of the regulation at its March 2024 meeting.

Fees charged for pharmacovigilance procedures in accordance with Regulation (EU) 658/2014 will not be revised in 2024 due to the implementation of Regulation (EU) 568/2024 coming into effect on 1 January 2025.

Share this page